Palisade Bio, Inc.
Palisade Bio, Inc. (PALI) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PALI · as of Jun 9, 2026
Key Statistics
Explore Palisade Bio, Inc. Data
pali stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 100.0%
The PALI analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month price target is $1.50, representing -13.79% downside from the current price of $1.74.
Competitors & Peers
pali competitorsPALI
ASBP
ATHA
BCTX
CRIS
CTXRStock Performance
Full HistoryAbout Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a comp…
what is palisade bio, inc. · pali stock overview · palisade bio, inc. company profile · who is palisade bio, inc. ceo · pali NASDAQ · palisade bio, inc. headquarters · palisade bio, inc. business segments
About Stock Overview & Key Data
Palisade Bio, Inc. (PALI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 30, 2007. As of the latest trading session, PALI stock price is $1.74, with a market capitalization of $302.0M. The stock has returned +145.59% over the past 12 months and -25.96% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Palisade Bio, Inc. stock is Buy, with an average 12-month price target of $1.50. In fiscal year 2025, Palisade Bio, Inc. reported revenue of — and net income of -$16.8M. For detailed data — including Palisade Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Palisade Bio, Inc. (PALI) stock price is $1.74. The stock is traded on NASDAQ under the ticker symbol PALI. The 52-week range is $0.53 – $2.86.